AMGN

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures and markets biologic medicines for serious illnesses such as cancer, cardiovascular disease, bone loss, inflammatory conditions and rare diseases. Its business model relies on extensive research‑and‑development investment, a portfolio of approved biologic therapies and a pipeline of candidates across all stages of clinical testing, with products sold worldwide through wholesale distributors and direct relationships with health‑care providers. Operating in the biotechnology and pharmaceutical sector, Amgen is one of the largest independent biotech firms, a component of the Dow Jones Industrial Average and recognized for flagship biologics like Enbrel, Neulasta, Prolia and Xgeva, as well as the recent addition of Horizon Therapeutics’ rare‑disease drugs.